Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Director · Chief Executive Officer | December 31, 2025 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date December 31, 2025 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 343,418 |
Reported balance
After 2025-12-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-31 · Grant · Acquired 951 · Balance 343,418 F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 344,871 |
Reported balance
After 2026-06-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-30 · Grant · Acquired 1,453 · Balance 344,871 F3: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is exempt under Rule 16b-3(c). F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 338,053 |
Reported balance
After 2026-07-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-07-01 · Tax withholding · Disposed 6,818 · Balance 338,053 F5: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025.
F3: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is exempt under Rule 16b-3(c).
F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2026.
F5: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 6, 2026 20:51 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 6,818 | $13.09 | $89,247.62 |
DisclosureSEC source: 0001346164-26-000006 · primarydocument.xml · nonDerivative · entry 3 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,053 F5 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2026. Read SEC document |
| June 30, 2026 Filed Jul 6, 2026 20:51 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 1,453 | $10.18 | $14,791.54 |
DisclosureSEC source: 0001346164-26-000006 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,871 F3 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is exempt under Rule 16b-3(c). F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2026. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:43 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 233,651 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0001346164-26-000004 · primarydocument.xml · derivative · entry 2 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,651 Underlying: Common Stock · 233,651 shares Expires 2036-01-06 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:43 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 144,864 | $0.00 | $0.00 |
DisclosureSEC source: 0001346164-26-000004 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,467 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 18,559 | $14.40 | $267,249.60 |
DisclosureSEC source: 0001346164-26-000002 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,603 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 3, 2022, January 3, 2023, January 2, 2024 and January 2, 2025. The number of shares withheld was determined on January 2, 2026 based on the closing price of the issuer's common stock on December 31, 2025. Read SEC document |
| December 31, 2025 Filed Jul 6, 2026 20:51 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 951 | $7.00 | $6,652.72 |
DisclosureSEC source: 0001346164-26-000006 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,418 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 22:38 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 20,811 | $12.62 | $262,634.82 |
DisclosureSEC source: 0001346164-25-000005 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,162 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.50 to $12.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 21:02 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 7,624 | $10.03 | $76,468.72 |
DisclosureSEC source: 0001346164-25-000003 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,973 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.00 to $10.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 7,734 | $10.02 | $77,494.68 |
DisclosureSEC source: 0001562180-25-006194 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,597 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.00 to $10.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 22:53 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 4,701 | $8.23 | $38,689.23 |
DisclosureSEC source: 0001562180-25-005334 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,331 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2025. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:59 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 476,606 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0001562180-25-000188 · primarydocument.xml · derivative · entry 3 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 476,606 Underlying: Common Stock · 476,606 shares Expires 2035-01-02 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:59 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 98,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000188 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,032 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2026, January 1, 2027, January 1, 2028 and January 1, 2029 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:59 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 11,917 | $7.73 | $92,118.41 |
DisclosureSEC source: 0001562180-25-000188 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,120 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022, January 3, 2023 and January 2, 2024. The number of shares withheld was determined on January 2, 2025 based on the closing price of the issuer's common stock on December 31, 2024. Read SEC document |
| January 02, 2025 Filed Jan 14, 2025 22:19 UTC Amendment | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 478,606 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0001562180-25-000360 · primarydocument.xml · derivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 478,606 Underlying: Common Stock · 478,606 shares Expires 2035-01-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 100 | $15.00 | $1,500.00 |
DisclosureSEC source: 0001562180-24-006014 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,037 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan as adopted on March 15, 2024. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 21:01 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 9,648 | $15.04 | $145,105.92 |
DisclosureSEC source: 0001562180-24-005874 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,137 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 11:56 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 272,189 | $0.00 Strike: $11.07 | $0.00 |
DisclosureSEC source: 0001562180-24-005567 · primarydocument.xml · derivative · entry 2 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,189 Underlying: Common Stock · 272,189 shares Expires 2034-07-01 F2 · derivative.exercise_date: The option vesting commencement date shall be July 1, 2024. The options shall have a term of 10 years from the date of grant, subject to continuous service of the optionee to the Issuer. The options shall become exercisable as follows: with respect to 1/4th of the shares subject to the option when the optionee completes 12 months of continuous service to the Issuer after the vesting commencement date, and with respect to 1/48th of the shares subject to the option when the optionee completes each month of continuous service to the Issuer thereafter. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 11:56 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 56,458 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005567 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,785 F1 · shares: The restricted stock unit (RSU) award vesting commencement date shall be July 1, 2024. 1/4th of the shares subject to the RSU shall vest on each of the first, second, third and fourth anniversaries of the first day of the month in which the RSU was granted, subject to the continuous service of the recipient to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:34 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 61,050 | $0.00 Strike: $18.34 | $0.00 |
DisclosureSEC source: 0001562180-24-000257 · primarydocument.xml · derivative · entry 3 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,050 Underlying: Common Stock · 61,050 shares Expires 2034-01-02 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2025 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:34 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 38,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000257 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,327 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2025, January 1, 2026, January 1, 2027 and January 1, 2028 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:34 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 8,120 | $17.95 | $145,754.00 |
DisclosureSEC source: 0001562180-24-000257 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,865 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022 and January 3, 2023. The number of shares withheld was determined on January 2, 2024 based on the closing price of the issuer's common stock on December 29, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 52,986 | $0.00 Strike: $22.25 | $0.00 |
DisclosureSEC source: 0001562180-23-000223 · primarydocument.xml · derivative · entry 3 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,986 Underlying: Common Stock · 52,986 shares Expires 2033-01-03 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 48 months following January 3, 2024 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 67,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000223 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,985 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2024, January 1, 2025, January 1, 2026 and January 1, 2027 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 2,076 | $22.68 | $47,083.68 |
DisclosureSEC source: 0001562180-23-000223 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,040 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021 and January 3, 2022. The number of shares withheld was determined on January 3, 2023 based on the closing price of the issuer's common stock on December 30, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 51,100 | $0.00 Strike: $34.31 | $0.00 |
DisclosureSEC source: 0001562180-22-000168 · primarydocument.xml · derivative · entry 3 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,100 Underlying: Common Stock · 51,100 shares Expires 2032-01-03 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 10,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000168 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,116 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 1,332 | $32.70 | $43,556.40 |
DisclosureSEC source: 0001562180-22-000168 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,416 Read SEC document |
| January 14, 2021 Filed Jan 14, 2021 23:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,372 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001562180-21-000345 · primarydocument.xml · derivative · entry 8 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,128 Underlying: Common Stock · 10,372 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 55,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2019, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| January 14, 2021 Filed Jan 14, 2021 23:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,240 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-21-000345 · primarydocument.xml · derivative · entry 7 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,240 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| January 14, 2021 Filed Jan 14, 2021 23:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 11,612 | $50.01 | $580,716.12 |
DisclosureSEC source: 0001562180-21-000345 · primarydocument.xml · nonDerivative · entry 5 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,748 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2021 Filed Jan 14, 2021 23:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,372 | $35.80 | $371,317.60 |
DisclosureSEC source: 0001562180-21-000345 · primarydocument.xml · nonDerivative · entry 4 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 14, 2021 Filed Jan 14, 2021 23:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,240 | $19.50 | $24,180.00 |
DisclosureSEC source: 0001562180-21-000345 · primarydocument.xml · nonDerivative · entry 3 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 23:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,700 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-21-000345 · primarydocument.xml · derivative · entry 6 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,240 Underlying: Common Stock · 1,700 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 23:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,700 | $50.03 | $85,051.00 |
DisclosureSEC source: 0001562180-21-000345 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,748 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 23:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,700 | $19.50 | $33,150.00 |
DisclosureSEC source: 0001562180-21-000345 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 21:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,185 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-21-000284 · primarydocument.xml · derivative · entry 3 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,940 Underlying: Common Stock · 5,185 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 21:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,185 | $50.01 | $259,301.85 |
DisclosureSEC source: 0001562180-21-000284 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,748 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 21:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 5,185 | $19.50 | $101,107.50 |
DisclosureSEC source: 0001562180-21-000284 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 13:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 62,300 | $0.00 Strike: $44.97 | $0.00 |
DisclosureSEC source: 0001562180-21-000143 · primarydocument.xml · derivative · entry 2 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,300 Underlying: Common Stock · 62,300 shares Expires 2031-01-04 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 4, 2022 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 13:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 13,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000143 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · Chief Oper. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,748 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2022, January 1, 2023, January 1, 2024 and January 1, 2025 while the recipient provides continuous service to the Issuer. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,633 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · derivative · entry 11 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,633 shares Expires 2025-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,692 | $51.37 | $189,658.04 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · nonDerivative · entry 7 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,948 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $51.07 to $51.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 8,872 | $50.13 | $444,753.36 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · nonDerivative · entry 6 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,640 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 6,633 | $22.00 | $145,926.00 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · nonDerivative · entry 5 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,253 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · derivative · entry 10 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Underlying: Common Stock · 4,253 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,928 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · derivative · entry 9 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,633 Underlying: Common Stock · 14,928 shares Expires 2025-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,479 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · derivative · entry 8 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 12,479 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 55,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2019, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 44,429 | $50.22 | $2,231,224.38 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · nonDerivative · entry 4 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,879 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 12,479 | $35.80 | $446,748.20 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · nonDerivative · entry 3 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 14,928 | $22.00 | $328,416.00 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.